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Background:  This study examined whether varenicline (VAR), or naltrexone (NTX), alone or in 
combination, reduces alcohol drinking in alcohol-preferring (P) rats with a genetic predisposition 
toward high voluntary alcohol intake.  
Methods:  Alcohol experienced P rats that had been drinking alcohol (15% v/v) for 2 hrs/day  
for 4 weeks were fed either vehicle (VEH), VAR alone (0.5, 1.0 or 2.0 mg/kg BW), NTX  alone 
(10.0, 15.0 or 20.0 mg/kg BW) or VAR + NTX in one of four dose combinations (0.5 VAR + 10.0 
NTX, 0.5 VAR + 15.0 NTX, 1.0 VAR + 10.0 NTX, or 1.0 VAR + 15.0 NTX) at 1 hour prior to 
alcohol access for 10 consecutive days and the effects on alcohol intake were assessed. 
Results:  When administered alone, VAR in doses of 0.5 or 1.0 mg/kg BW did not alter alcohol 
intake but a dose of 2.0 mg/kg BW decreased alcohol intake.  This effect disappeared when 
drug treatment was terminated.  NTX in doses of 10.0 and 15.0 mg/kg BW did not alter alcohol 
intake but a dose of 20.0 mg/kg BW decreased alcohol intake.  Combining low doses of VAR 
and NTX into a single medication reduced alcohol intake as well as did high doses of each drug 
alone.  Reduced alcohol intake occurred immediately after onset of treatment with the combined 
medication and continued throughout prolonged treatment. 
Conclusions: Low doses of VAR and NTX, when combined in a single medication, reduce 
alcohol intake in a rodent model of alcoholism.  This approach has the advantage of reducing 
potential side effects associated with each drug.  Lowering the dose of NTX and VAR in a 
combined treatment approach that maintains efficacy while reducing the incidence of negative 
side-effects may increase patient compliance and improve clinical outcomes for alcoholics and 
heavy drinkers who want to reduce their alcohol intake.  
Keywords: alcohol drinking, alcohol treatment, selectively bred rats, naltrexone, varenicline
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Introduction 
Alcoholism is the most prevalent and widespread of all addictive diseases and development of 
effective treatments for alcohol abuse and alcoholism is a world-wide priority. Only three drugs 
have been approved by the FDA for the treatment of alcohol dependence: disulfiram (antibuse), 
acamprosate, and naltrexone (NTX; Trexan or Revia) (Anton et al., 2006). NTX is more effective 
than is acamprosate (Maisel et al., 2013) and exhibits better compliance than does disulfiram  
(Anton et al., 2006; Fuller et al., 1986), but it remains under-utilized because its efficacy is 
modest (Froehlich et al., 2003; O’Malley et al., 2003), it is not effective for all alcoholics 
(Kranzler et al., 2000; Krystal et al., 2001), and, when it is effective, many alcoholics fail to 
maintain initial treatment gains and relapse to heavy drinking (Anton et al., 2006; Krystal et al., 
2001; Krishnan-Sarin et al., 2007). Clearly, additional medications for the treatment of alcohol 
abuse and alcoholism are needed.  
Opioid antagonists were first shown to decrease alcohol drinking in rats selectively bred for high 
voluntary alcohol intake (Froehlich et al. 1990; 1991a; Froehlich and Li, 1991b). This preclinical 
work led to studies on the effects of naltrexone (NTX), a nonspecific opioid receptor antagonist, 
on alcohol drinking in humans. NTX decreases alcohol intake and reduces alcohol relapse rates 
in alcoholics and heavy drinkers (O’Malley et al., 1992; Volpicelli et al., 1992).  It reduces the 
reinforcing effects of alcohol by antagonizing beta-endorphin stimulated dopamine (DA) release 
in the brain during alcohol exposure (DiChiara and Imperato, 1988; Imperato and DiChiara, 
1986; Koob et al., 1992). Subjects receiving NTX reported that the “high” they experienced from 
alcohol was less than they had previously experienced in the absence of NTX, and was less 
than they had expected to experience when they drank alcohol (Volpicelli et al., 1995). The 
alcoholics who “slipped” and drank alcohol while taking NTX consumed less alcohol than did 
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those taking placebo, were able to stop drinking after a few drinks, and were less likely to drink 
to intoxication.  
Varenicline (VAR), an α4β2 nicotinic acetylcholinergic receptor partial agonist, marketed as 
CHANTIX® in the United States, and as CHAMPIX® in Europe and elsewhere, was FDA 
approved for smoking cessation in 2006.  Recent preclinical studies suggest that VAR also 
reduces alcohol, as well as nicotine, intake in rats and humans by blocking both alcohol and 
nicotine-induced excitation of the DA system (Chatterjee et al., 2011; Fucito et al., 2011; Mckee 
et al., 2009; Steensland et al., 2007). In a preliminary study, we found that VAR decreases 
alcohol intake in a rodent model of alcoholism; that is, in rats selectively bred for alcohol 
preference and high voluntary alcohol drinking (“P” rats). This agrees well with other reports that 
VAR reduces operant self-administration of alcohol in rats (Bito-Onon et al, 2011) and reduces 
alcohol drinking in Wistar rats induced to drink alcohol via the sucrose fade procedure 
(Steensland et al., 2007). In humans, a preliminary study in heavy alcohol drinking smokers 
reported that VAR (2.0 mg/day), compared to placebo, decreased alcohol craving, the number 
of drinks consumed,  and the subjective reinforcing effects of alcohol (e.g., “high” or 
“intoxication”), and increased the likelihood of abstaining from drinking (McKee et al., 2009). The 
subjects were not deprived of nicotine in this study which indicates that VAR decreased alcohol 
drinking independent of its effects on nicotine.  O’Malley and colleagues gave 30 heavy drinking 
smokers VAR (2.0 mg/day) or placebo for 5 or 8 weeks and found  that VAR was well tolerated, 
and compared to placebo, VAR decreased alcohol craving as well as the number of heavy 
alcohol drinking days (Fucito et al., 2011).  
Given that both VAR and NTX, when administered alone, can decrease alcohol drinking in rats 
and humans, we hypothesized that VAR and NTX, when combined, would act more effectively 
to decrease alcohol drinking than would either drug alone. The fact that VAR and NTX, when 
given alone, reduce alcohol drinking in both P rats and in heavy drinkers lends predictive validity 
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to the use of P rats as a rodent model of alcoholism that is appropriate for characterizing the 
effects of combining VAR+NTX on alcohol drinking  (Froehlich et al., 2003; O’Malley et al., 
2003). The current study addressed the following questions in P rats: (1) Does VAR+NTX in 
combination reduce alcohol intake more effectively than dose either drug alone? (2) Does a 
reduction in drinking occur quickly after onset of treatment with the combined drug? And (3) is 
the reduction sustained throughout prolonged administration? 
 
MATERIALS AND METHODS 
Subjects 
Fifty-nine alcohol-naïve male P rats from the 77th generation of selective breeding for alcohol 
preference (P line) served as subjects in all studies except when blood alcohol concentration 
(BAC) was examined.  In that study a subset of 15 of the 59 rats served as subjects.  At the 
onset of the study, all rats were between 148 to 158 days of age.  The rats were individually 
housed in stainless steel hanging cages located in an isolated vivarium with controlled 
temperature (21+1°C) and a 12 hour light/dark cycle with lights off at 0900 hrs.  Standard rodent 
chow (Laboratory Rodent Diet #7001, Harlan Teklad, Madison, WI) and water were available ad 
libitum.  All experimental procedures were approved by the Indiana University Institutional 
Animal Care and use Committee and conducted in strict compliance with the NIH Guide for the 
Care and Use of Laboratory Animals. 
Alcohol Solution   
A 15% (v/v) alcohol solution was prepared by diluting 95% alcohol (ethanol) with distilled, 
deionized water. The alcohol solution and water were presented in separate calibrated glass 
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drinking tubes and daily intakes were recorded to the nearest ml.  Alcohol intake in mls was 
converted to g alcohol/kg BW prior to data analysis 
 
Drug Preparation and Oral Delivery 
Varenicline tartrate (VAR) (Pfizer Int., Groton, CT) and naltrexone hydrochloride (NTX) (Sigma-
Aldrich, St. Louis, MO,) were dissolved in deionized, distilled water using sonication at 55o C.  
The stock solution containing drug was added to a sweetened gelatin solution comprised of 
berry flavored Jell-O and gelatin in distilled, deionized water. VAR and NTX, expressed as free 
base masses, were added to the gelatin solution to provide the following doses: 0.5, 1.0, and 
2.0 mg of varenicline/3.0 ml solution/kg BW; 10, 15, and 20 mg of Naltrexone /3.0 ml solution/kg 
BW; and 0.5 or 1 mg VAR + 15 mg NTX/3.0 ml solution/kg BW, and 0.5 or 1 mg VAR + 10 mg 
NTX/3.0 ml solution/kg BW.   While still hot, the gelatin solution containing the drug(s) was 
aliquoted into star shaped molds, one per rat, with the volume of each aliquot determined by the 
final concentration of the gelatin (mg drug/ml of gelatin solution) and the body weight of the 
animal in order to produce individual drug dosing, one dose per day per rat, as previously 
described (Froehlich et al., 2013a). The flavored, star-shaped pieces of gelatin (approximately 
1.8 g), containing VAR and NTX, alone or in combination, were fed to the rats once each day by 
inserting them through a hole in the front of the cage. The rats consistently ate the gelatin within 
1 minute. Cages were checked to confirm that no pieces of gelatin were dropped. On the rare 
occasion that rats dropped the gelatin star, the star was re-fed to the rat. Gelatin was fed each 
day at 1 hour prior to onset of the daily 2-hour alcohol access period, except in one study where 
the time between oral drug delivery and onset of VAR treatment was the dependent variable.  
All rats were fed vehicle gelatin (no drug) once a day for 5 consecutive days prior to the initiation 
of drug treatment in order to acquaint them with the oral drug administration procedure.   We 
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have previously found that consumption of the flavored gelatin with no drug (vehicle) at 1 hour 
prior to daily 2-hour access to alcohol does not alter alcohol intake (data not shown). 
Specifically, the average daily 2-hour alcohol intake during the 5 days prior to consumption of 
vehicle gelatin was 1.8 g/kg BW (N = 64 adult male P rats) and average daily 2-hour alcohol 
intake in the same rats during 5 days of consumption of vehicle gelatin was 1.7 g/kg BW.  We 
routinely use this oral drug delivery approach successfully for the prolonged administration of 
drugs such as prazosin, NTX, or varenicline (Froehlich et al., 2013a, 2013b). It is appropriate for 
any drug that is water soluble and orally active.  
 
Alcohol Drinking Induction 
All rats were provided with access to food, water and a 15% (v/v) alcohol solution and the 
alcohol solution was introduced using a “step-down” procedure as previously described 
(Froehlich et al, 2013a; 2013b) in order to maximize alcohol intake during a restricted two hour 
daily alcohol access period.  Alcohol was first available for 8 hours a day for 5 days, then 
access was reduced to 4 hours a day for 10 days, and finally to 2 hours a day for 28 days. 
Throughout each study rats were maintained with free access to food and water and scheduled 
access to the 15% (v/v) alcohol solution for 2 hours a day (from 1000 hours, onset of dark, to 
1200 hours).  Alcohol and water intake were recorded daily and body weight was recorded once 
a week. This step-down procedure produces stable drinking at approximately 2.0g/kg BW/2 
hours in P rats (Rasmussen et al., 2009). All rats had served as subjects in a prior study with 
varenicline, 11 weeks earlier, and were maintained with ad lib food and water and 2-hr daily 
access to alcohol (15% v/v) for 4 additional weeks prior to introducing the alcohol drinking 
induction protocol.    
 
Assigning Rats to Groups 
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Rats were ranked in descending order of average daily 2h alcohol intake for 5 consecutive days 
prior to onset of drug treatment and were assigned to dose groups in a manner that ensured 
that alcohol intake did not differ between groups prior to initiation of drug treatment, as 
previously described (Froehlich et. al., 2013a; 2013b). 
 
Experimental Design 
Varenicline on alcohol intake 
Rats were fed VAR (0.5, 1.0, 2.0 mg/kg BW) or vehicle in gelatin 1-hr prior to onset of each daily 
2-hr alcohol access period for 5 days/week for 2 weeks.  This was followed by continued ad 
libitum access to food, water, and continued daily 2h access to alcohol without drug for 2 weeks 
(post drug days).  In order to assess whether a longer lead time between drug administration 
and alcohol access would increase the efficacy of VAR,  a subset of forty-nine male P rats were  
randomly selected and were fed vehicle gelatin stars at 2 hours prior to onset of daily 2-hour 
alcohol access for 5 days and daily alcohol intake was assessed. They were then assigned to 
VAR drug dose groups as previously described and were fed VAR (0.5, 1.0, or 2.0 mg/kg BW) 
or vehicle, once daily, at 2 hours prior to onset of the daily 2 hour  alcohol access period for 5 
consecutive days. Doses of VAR above 2.0 mg/kg were not used because higher doses of VAR 
are no longer specific for the alpha-2-beta-4 and/or alpha-7 nicotine acetylcholine receptors 
(Rollema et. al., 2006; conversation with Hans Rollema), and doses above 3.0 mg/kg decrease 
food intake in rats, presumably via induction of nausea (O’Conner et. al, 2009; Faessel et al., 
2006). 
Naltrexone on alcohol intake 
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Rats were fed  NTX (10.0, 15.0, or 20.0mg/kg BW) or vehicle in gelatin stars at  1 hour prior to 
onset of each daily 2 hour alcohol access period for 5 days a week for  2 weeks.  
Varenicline + Naltrexone Combined  
 Another group of alcohol naïve adult male P rats (N=59) were induced to drink alcohol as 
described above. They were then maintained with ad lib food and water and 2-hr daily access to 
alcohol (15% v/v) for 4 weeks prior to onset of drug treatment.  All rats were counterbalanced 
and assigned to drug dose groups as described above.  Rats were fed vehicle or VAR + NTX 
(0.5 VAR+ 10.0 NTX or 0.5 VAR + 15.0 NTX or 1.0 VAR + 10.0 NTX or 1.0 VAR + 15.0 NTX) in 
gelatin stars at 1 hour prior to onset of each daily 2-hr alcohol access period for 5 days a week 
for 3 weeks.   The VAR and NTX doses that were chosen to be combined were those that were 
ineffective in decreasing alcohol intake when given alone.  
Varenicline + Naltrexone on blood alcohol concentration (BAC) 
After completion of the VAR+NTX study, 15 P rats were randomly selected from that study and 
were maintained with ad libitum access to food and water and limited access to alcohol (15% 
v/v) for 2 hours a day for 5 weeks.  The rats were counterbalanced based on alcohol intake and 
assigned to the vehicle or the drug treatment group as described above. The rats were fed 
gelatin stars gummies containing no drug (vehicle) or containing 1.0 mg VAR + 10 mg NTX/kg 
BW at 1 hour prior to onset of the daily 2-hour alcohol access period for 5 days prior to an 
intragastric (IG) infusion of alcohol and determination of BAC.  It is known that naltrexone alone 
does not alter BAC (Linesman et al., 1997) but the effect of VAR on BAC is not known.  We 
chose the highest dose of VAR that had been used in combination with NTX so that if the drug 
combination did alter BAC, it would be seen at this dose. On the night before IG infusion and 
BAC determination food was removed from all rat’s cages and each rat was given 7 grams of 
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food which served to minimize and equate the amount of food present in the stomach at time of 
IG infusion of alcohol. This serves to reduce individual differences in the rate of alcohol 
absorption from the stomach, and reduces variability in BAC following an alcohol infusion.  On 
the day of BAC determination, rats were given IG alcohol in a dose of 2.0 g alcohol/10.1 mls of 
a 25% v/v alcohol solution/kg BW. This dose is similar to the amount of alcohol that P rats 
consume in a daily 2-hr alcohol access period (Froehlich et al., 2013a; 2013b; Froehlich et al., 
2015; Rassmusen et al., 2009). This dose produces physiologically relevant BACs (Murphy et 
al. 1986) that are almost twice the human legal limit for intoxication (Li et al., 1998), but are 
below the threshold that produces damage to the gastric mucosa (Gillespe and Lucas, 1961) or 
that induces smooth muscle paralysis (Bernard et al., 1964). The volume infused is also well 
below the gastric capacity of an adult rat (Bull and Pitts, 1971). Tail blood was collected at 15, 
30, 60, 90, 120, 180, and 240 minutes after onset of the IG alcohol infusion. A razor blade was 
used to cut the tip (< 1 mm) of the tail and 0.075 ml of blood was collected into a heparinized 
capillary tube, dispensed into an ice-cold 0.5-ml microcentrifuge tube, sealed, and centrifuged at 
4 0C. Spontaneous bleeding stopped immediately after sample collection and subsequent 
samples were collected by removing the coagulate from the tip of the tail. Plasma was extracted 
and frozen at -200C until assayed for alcohol content by gas chromatography using a Hewlett-
Packard 6890 series gas chromatography with auto injection. The column used was a HP-
Innowax (crosslinked polyethylene glycol, 30 m x 0.25 mm x 0.25 um), and the internal standard 
was 1-propanol.   
Data Analysis 
Alcohol intake was analyzed using 2-way repeated-measures analysis of variance (ANOVA) 
(treatment X day, RM on day) followed, when justified, by pairwise multiple comparisons using 
either Fisher’s least significant difference (LSD) test when the interaction term was significant or 
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Dunnett’s multiple comparisons against a single mean when the interaction term was not 
significant.  Significance was accepted at p<0.05, and data are represented as means + SE.  
BACs were analyzed using a 2-way repeated-measures ANOVA (dose x time, with RM on time).  
Data were analyzed for extreme scores using the Dixon extreme score test and a conservative 
cutoff of p<0.01.  Only 3 scores (in experiment 2) were excluded from the data set prior to 
statistical analyses.  Extreme scores were replaced with the mean alcohol intake on the day 
prior to, and the day following the day when the extreme score was recorded. Consumption of 
less than ¾ of the gelatin star resulted in exclusion of the drinking score for that rat on that day 
which occurred 4 times in the NTX alone study and 1 time in the VAR 1 hour lead time study.  
 
RESULTS 
Alcohol Drinking Induction   
During the first phase of alcohol drinking induction, P rats consumed roughly 4.0 g alcohol/kg 
BW per day during an 8-hr free-choice between the alcohol solution (15% v/v) and water. This 
corresponds to a 70-kg person (154 pounds) drinking 5-6 standard drinks. A standard drink 
contains approximately 14 g of alcohol (NIAAA, 2008). The alcohol elimination rate (AER) of 
rats is 0.44 g/kg BW/hour (Parselak et al., 2004), which is approximately 4 times the AER of 
humans (0.11 g/kg BW/h) (Forsander and Sinclair, 1992). During drinking induction, when the 
daily alcohol access period was reduced to 2 hours a day, the P rats consumed an average of 
approximately 2.0 g alcohol /kg BW, which is equivalent to a human drinking 3 drinks in two 
hours (Figure 1).  
Effect of VAR alone on Alcohol Intake (1 hour lead time) 
12 
 
 
Alcohol intake during the 2 weeks of VAR treatment (5 days/week) was analyzed with a two-way 
RM ANOVA (dose X day, RM on day). There was a significant effect of dose, F (3, 55)= 9.284, 
p<0.001, a significant effect of day, F (9, 495) = 10.23, p<0.001, and no significant interaction 
(p=0.78) (Figure 2 A) . Dunnett’s multiple comparisons against a single mean revealed that only 
the 2.0 mg/kg BW dose of VAR significantly reduced alcohol intake (p<0.001) when compared 
to vehicle (Figure 2 B). To further assess the effect of day, one-way ANOVAs were conducted, 
one for each of the 10 days of treatment, for VAR in a dose of 2.0 mg/kg BW.  VAR  reduced 
alcohol intake on all 10 days of drug treatment (p<0.05; p<0.01; or p<0.001, depending on the 
day) when compared to vehicle.   
With regard to alcohol intake following termination of drug treatment, there was a strong trend 
toward a significant effect of dose (p=0.06), a significant effect of day [F(4, 220)= 11.22, 
p<0.001], and no interaction (p=0.55) (Figure 2 A). Visual inspection of the data revealed that 
the trend for dose was due to the 2.0 mg/kg BW dose of VAR which was further analyzed with 
separate one-way analyses, one for each post drug day, comparing 2.0 VAR and VEH. There 
was a very strong trend toward a reduction of alcohol intake on day 1 following termination of 
drug treatment (p=0.053), but no significant effect was seen on any days thereafter.  
Effect of VAR Alone on Alcohol Intake (2 hour lead time)  
The two-way RM ANOVA (dose x day, RM on day) on days 1-5 of drug treatment revealed a 
significant effect of dose, F (3, 44)= 2.91, p<0.05, no significant effect of day (p=0.12), and no 
significant interaction (p=0.77). Dunnett’s multiple comparisons against a single mean revealed 
that no dose significantly decreased or increased alcohol consumption when compared to 
vehicle (Figure 3). 
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With regard to alcohol intake following termination of treatment, there was no effect of dose 
(p=0.95), a significant effect of day [F(4, 175)= 3.17, p<0.05], and no interaction (p=0.52). 
Effect of NTX alone on Alcohol Intake 
Alcohol intake during the 2 weeks of NTX treatment (5 days/week) was analyzed using a two-
way RM ANOVA (dose X day, RM on day).  The results revealed that there was a significant 
effect of treatment, F (3, 55)= 7.04, p<0.001, a significant effect of day, F (9, 495)= 5.87, 
p<0.001, but no significant interaction (p=0.32) (Figure 4 A). Dunnett’s multiple comparisons 
against a single mean revealed that only the 20 mg dose of NTX significantly reduced (p<0.001) 
alcohol intake when compared with vehicle (Figure 4 B). 
One-way ANOVAs were conducted, one for each day, to analyze how long the treatment effect 
of 20.0 mg NTX/kg BW lasted. The ANOVAs revealed that 20.0 NTX reduced alcohol intake on 
all 10 days of drug treatment when compared to vehicle (p<0.05, p<0.01, or p<0.001 depending 
on the day) (Figure 4 A). 
With regard to alcohol intake following termination of treatment, there was no effect of dose 
(p=0.17), a significant effect of day [F(4, 220)= 7.80, p<0.001], and no interaction (p=0.82). 
 
Effect of VAR+NTX on Alcohol Intake 
Alcohol intake during the first week of combination drug treatment (days 1-5) was analyzed with 
a two-way RM ANOVA (treatment X day with repeated measures on day).  There were 
significant effects of treatment, F (4, 54) = 15.27, p<0.001, and day, F (4, 216) = 3.98, p <0.01, 
but no significant interaction (p=0.32).  Dunnett’s multiple comparison against a single mean 
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revealed that alcohol intake in all 4 combination drug treatment groups was significantly lower 
than intake in the vehicle treated group (p<0.001) (Figure 5B). 
Alcohol intake during the entire 3 weeks of combination drug treatment (5 days/week) was 
analyzed with a two-way RM ANOVA (dose X day, with repeated measures on day). There were 
significant effects of treatment, F (4, 54) = 8.07, p<0.001, and day F (14, 756) =15.84, p<0.001, 
and a significant treatment x day interaction, F (56, 756) = 1.83, p<0.001 (Figure 5 A). Fisher’s 
LSD test revealed that alcohol intake in all dose combination groups was significantly lower than 
alcohol intake in the vehicle treated group [0.5 VAR + 10 NTX (p=0.055), 0.5 VAR + 15 NTX 
(p<0.05), 1.0 VAR + 10 NTX (p<0.001), 1.0 VAR + 15 NTX (p<0.001)] (Figure 5 C). Fisher’s 
LSD test also revealed that alcohol intake in the highest VAR dose groups (1.0 VAR + 10 NTX 
and 1.0 VAR + 15.0 NTX), was significantly lower than intake in the 0.5 VAR dose groups 
(p<0.01 and p<0.01 respectively) regardless of the NTX dose that VAR was combined with.  
Further pairwise comparisons with Fisher’s LSD revealed that, when compared to VEH, 1.0 
VAR + 15.0 NTX reduced alcohol intake on 14 of the 15 treatment days (p<0.05, p<0.01, or 
p<0.001, depending on the day), 1.0 VAR + 10.0 NTX reduced alcohol on 11 of the 15 
treatment days (p<0.05, p<0.01, or p<0.001, depending on the day), 0.5 VAR + 15.0 NTX 
reduced alcohol intake on 6 of the 15 treatment days (p<0.05, p<0.01, or p<0.001, depending 
on the day), and 0.5 VAR + 10.0 NTX reduced alcohol intake on only 5 of the 15 treatment days 
(p<0.05, p<0.01, or p<0.001, depending on the day). 
With regard to alcohol intake after termination of VAR+NTX treatment (Figure 5 A), there was 
no effect of treatment (p=0.68), or day (p=0.17), and no interaction (p=0.94). 
 
Effect of VAR+NTX on BAC 
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With regard to the effect of 5 days of treatment (VAR 1.0 mg/kg BW +NTX 10.0 mg/kg BW) on 
BAC,  a 2-way rm ANOVA (treatment X time with repeated measure on time) revealed no 
significant effect of treatment (p=0.74), a significant effect of time (p<0.001), and no significant 
interaction (p=0.69). The peak BAC was 150-170 mg% at 30-90 minutes after I.G. infusion with 
2.0 g alcohol /kg BW in both the group pretreated with vehicle and in the group pretreated with 
1.0 mg/kg VAR + 10 mg/kg NTX (Figure 6 A). 
With regard to the alcohol intake during the 5 days of treatment (VAR 1.0 mg/kg BW +NTX 10.0 
mg/kg BW) prior to BAC determination, there was a significant effect of dose [F(1, 16)= 7.38, 
p<0.05], no effect of day (p=0.08), and no interaction (p=0.92). Dunnet’s post-hoc analysis 
revealed that the treatment of 1.0 VAR + 15 NTX reduced alcohol intake when compared to 
vehicle (Figure 6 B).  
DISCUSSION 
Given the global prevalence of alcohol addiction, it is critical that people seeking help have 
access to effective treatments including medications as well as psychosocial interventions.  
Currently there are only three FDA approved drugs for the treatment of alcohol addiction: 
disulfiram (antibuse) which was approved in 1949, naltrexone (Trexan) which was approved in 
1994, and acamprosate (campral) which was approved in 2004.  None of these drugs are 
effective for all alcoholics and none are without side effects.  Clearly, additional medications are 
needed to assist alcoholics and heavy drinkers in reducing their alcohol intake when they seek 
treatment on a voluntary basis as well as when treatment for alcohol abuse is delivered in 
closed care facilities.   
Our research group has had a long-standing interest in identifying medications that have the 
potential to reduce alcohol abuse and alcoholism safely and effectively. Naltrexone has been 
16 
 
 
extensively characterized in both rodents and humans (for review see Froehlich et al., 2003; 
O’Malley et al., 2003) and is the most effective medication available for decreasing alcohol 
intake (Maisel et al., 2013). However, NTX is underutilized because its efficacy is modest, it is 
not without side effects, it is not effective for all alcoholics, and, when it is effective, a number of 
alcoholics fail to maintain initial treatment gains and relapse to heavy drinking.  We have 
recently begun to investigate the potential value of combining naltrexone with other medications 
in order to allow efficacy to be achieved at lower doses thus avoiding potential side effects.  For 
instance, we have found that prazosin, a drug used to treat post-traumatic stress disorder 
(PTSD), decreases alcohol drinking in a rodent model of alcoholism when administered alone 
(Froehlich et al., 2013a; Froehlich et al., 2015; Rasmussen 2009) and combining low dose NTX 
with low dose prazosin, in a single medication, decreases alcohol drinking more effectively than 
does either drug alone (Froehlich et al., 2013b).   
The current study focused on varenicline (Chantix or VAR), a relatively new drug that has been 
well characterized with regard to its effect on nicotine intake.  VAR is marketed for, and used to, 
decrease cigarette smoking but a few studies have reported that it also decreases alcohol 
intake (Bilo-Onon, 2011; Chatterjee et al., 2011; Ericson et al., 2009). For instance, a recent 
study of cigarette smokers, who also drank alcohol heavily, reported that while VAR decreased 
smoking, as expected, a combination of VAR and NTX also reduced alcohol drinking and, when 
compared to placebo, reduced the “high” produced by alcohol (Ray et al, 2014). This may be 
due, in part, to the fact that NTX and VAR share a common mechanism of action with regard to 
the dopaminergic system. Alcohol stimulates the release of endogenous opioids (for review see 
Froehlich and Li 1993; 1994) which in turn results in an increase in DA release in the nucleus 
accumbens (Di Chiara and Imperato 1988; Imperato and Di Chiara 1986; Weiss et al., 1993). 
This increase in DA release mediates the euphoria that accompanies alcohol drinking and that 
serves to reinforce subsequent alcohol drinking (Samson et al., 1992). NTX blocks opioid 
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receptors which results in decreased alcohol-induced DA release in the nucleus accumbens 
(Benjamin et al., 1993; Dudek et al., 2016) thus reducing alcohol-induced euphoria and the 
reinforcing properties of alcohol. VAR also decreases DA release in the nucleus accumbens by 
binding to the α4β2 nicotinic receptors (Rollema et al., 2007; Hendrickson et al., 2013). Hence, 
both naltrexone and varenicline reduce alcohol-induced euphoria and alcohol reinforcement 
through inhibition of alcohol-induced DA release.    
Based on our prior work with drug combinations (Froehlich et al., 2013b; Rasmussen et al., 
2014; 2015), we predicted that combining an ineffective dose of NTX with an ineffective dose of 
VAR in a single medication would decrease alcohol intake more effectively than would either 
drug alone. The results of the current study support this prediction. During week one of 
treatment low doses of VAR (0.5, and 1.0 mg/kg BW) and low doses of NTX (10mg, and 
15mg/kg BW), when given alone, were not effective in decreasing alcohol drinking. However, 
when ineffective doses of the two drugs were combined, alcohol intake was significantly 
reduced when compared to vehicle, and the effect was seen in all low dose combinations 
tested. Of particular importance is the fact that the reduction in alcohol drinking occurred 
immediately after onset of treatment with the combined medication and continued throughout 3 
weeks of treatment. The low dose combination decreased alcohol intake as effectively as did 
higher doses of VAR (2.0 mg/kg BW) or NTX (20mg/kg BW) alone.  The reduction in alcohol 
intake seen following VAR+NTX treatment was not due to drug-induced changes in alcohol 
absorption or clearance as evidenced by a similar magnitude and time course of the BAC 
following an IG infusion of alcohol in rats previously treated for 5 days with the drug combination 
(1.0 VAR + 10.0 NTX) or with vehicle.  The drug combination decreased alcohol intake on all 
five days of treatment but did not alter BAC in response to an IG infusion of alcohol.   
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The ability of  VAR alone, NTX alone and VAR+NTX  to decrease alcohol intake disappeared 
after termination of drug treatment.  However, there was a strong trend toward a significant 
effect of high dose VAR in reducing alcohol intake on the day following termination of treatment 
which suggests that the duration of action of VAR may surpass that of NTX. 
The doses of NTX used in the current study (10.0 - 20.0 mg/kg BW) are higher than those used 
via non-oral routes. This is because NTX has a low bioavailability when administered orally 
(Hussain et al., 1987). Consequently, a larger dose is required to produce a comparable serum 
level of NTX to that seen when lower doses are given via non-oral routes. In rats, NTX has an 
oral bioavailability of 1%, which is lower than the 15-25% bioavailability found in humans 
(Goodman and Gilman, 2011). This low oral potency of NTX in rats is due to a rapid first pass 
metabolism, rather than to gastro-intestinal factors (Shepard et al., 1985). In contrast, 
varenicline is well absorbed after oral administration and has a bioavailability of >87% (Obach et 
al. 2005; and Goodman and Gilman, 2011). Therefore, a given dose of varenicline is equally 
effective if given via non-oral or oral routes (Steensland et al., 2007; Mckee et al., 2009). We are 
not aware of any interactions between NTX and VAR that would alter side effects associated 
with the combination in rodents or humans. 
When administered orally in rodents (via gavage), the t1/2 of varenicline is 4.0 +/- 0.9 hours 
(Obach et al., 2005).   In the current study, we compared the effect of two lead times, 1 hour 
and 2 hours, between oral administration of VAR and onset of access to alcohol.  We found that 
VAR (2.0 mg/kg BW) was effective in reducing alcohol intake when given one hour prior to 
onset of alcohol access, but was not effective when given two hours prior to alcohol. The 1 hour 
lead time appears optimal for VAR-induced reductions in alcohol drinking when administered 
orally in rodents.   
It should be noted that neither VAR nor NTX, alone or in combination, eliminated alcohol 
drinking in P rats. While elimination of drinking (complete abstinence), can be achieved by 
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humans, this usually occurs when psychosocial approaches are combined with medication in 
individuals with a high motivation to stop drinking.  Rats lack the psychosocial elements 
(counseling, network support, social pressure) that contribute significantly to abstinence in 
humans and hence an elimination of alcohol drinking would not be expected in the current study 
in which rats received medication alone.  The fact that varenicline + naltrexone, in a combined 
medication, reduced alcohol drinking without the contribution of psychosocial elements suggests 
that these drugs may be particularly effective for alcoholics and heavy drinkers who are 
motivated to reduce their drinking through the use of medications together with psychosocial 
interventions as part of a comprehensive treatment program for alcohol use disorders. 
Using lower doses of drugs in combination has two potential benefits. First, use of low doses 
may eliminate adverse side effects.  This is important with regard to NTX, which can produce 
occasional malaise, depression-like symptoms, and dysphoria (Hollister et al., 1981; Malcolm et 
al., 1987; Oncken et al., 2001) and with regard to VAR which can produce sleep disorders, 
increased fatigue, and jaundice in the case of drug-induced liver injury (Mogensen et al., 2015; 
Thomas et al., 2015).  In the current study, a low dose of VAR+NTX was as effective in 
decreasing alcohol intake as was a high dose of either drug alone even during the first week of 
drug treatment. The fact that low dose VAR+NTX was effective in the first week of treatment, 
when the probability of relapse in alcoholics is high, is important because inpatients are typically 
instructed to abstain from alcohol for several days before starting a drug treatment, during which 
time alcohol craving escalates (personal conversation, Dr. Tim Kelley, Medical Director, 
Fairbanks Alcohol and Drug Treatment Center, 2012).  A fast acting medication may help 
prevent relapse in these patients. For those in the outpatient setting, increased effectiveness of 
a combined medication in the first week of treatment is likely to promote a positive long-term 
outcome because an immediate positive effect may reinforce the decision to continue voluntary 
treatment (Christensen, 1978).  
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There is an urgent need for new approaches to treat alcoholism and alcohol abuse.  A single 
medication may not be optimal for all stages of alcohol abuse or for different types of alcohol 
use disorders. A “personalized medicine” or “precision medicine” approach would allow for 
tailoring of drug combinations to meet the needs of individual patients. The results of the current 
study suggest that a combination of low dose VAR + NTX, may be effective when used early in 
the treatment process by alcoholics and heavy drinkers who do not respond well to a single 
medication.  
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FIGURE LEGENDS 
Figure 1. Alcohol intake in male P rats given scheduled access to alcohol (15% v/v) for 8 hours 
a day for 4 days, followed by 4 hours a day for 10 days, and 2 hours a day for 28 days prior to 
the initiation of drug treatment. Each point represents the mean ± SE. 
 
Figure 2.  (A) Effect of oral varenicline (VAR) (0.5, 1.0 or 2.0 mg/kg BW) or vehicle (VEH), given 
one hour prior to alcohol access, on alcohol intake in male P rats given access to alcohol (15% 
v/v) for 2 hours a day. (B) Effect of VAR or VEH on mean alcohol intake over the 10 days of 
drug treatment. *** p<0.001 vs VEH. Each point represents the mean  S.E. 
 
Figure 3. Effect of oral varenicline (VAR) (0, 0.5, 1.0, or 2.0 mg/kg BW) or vehicle (VEH), given 
two hours prior to alcohol access, on alcohol intake in male P rats given access to alcohol (15% 
v/v) for 2 hours a day. Each point represents the mean  S.E. 
 
Figure 4. (A) Effect of oral naltrexone (NTX) (10.0, 15.0, or 20.0 mg/kg BW) or vehicle (VEH) on 
alcohol intake in male P rats given access to alcohol (15% v/v) for 2 hours a day. (B) Effect of 
NTX or VEH on mean alcohol intake over the 10 days of drug treatment. *** p<0.001 vs VEH. 
Each point represents the mean  S.E. 
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Figure 5. (A) Effect of oral varenicline + naltrexone (VAR + NTX) (0.5 + 10.0, 0.5 + 15.0, 1.0 + 
10.0, or 1.0 + 15.0 mg/kg BW) or vehicle (VEH) on alcohol intake in male P rats given access to 
alcohol (15% v/v) for 2 hours a day. (B) Effect of VAR+NTX VEH on mean alcohol intake over 
the first 5 days of drug treatment. (C) Effect of VAR+NTX or VEH on mean alcohol intake over 
the full 15 days of drug treatment. * p<0.05, ** p<0.01, ***p<0.001 vs VEH. Each point 
represents the mean  S.E. 
 
Figure 6. (A) Effect of oral varenicline + naltrexone (VAR+NTX) (1.0mg + 10.0mg) or vehicle 
(VEH) on blood alcohol concentration (BAC) following an intragastric (IG) infusion of alcohol 
(2.0 g/kg BW) in P rats. (B) Effect of VAR+NTX (1.0 + 10.0 mg/kg BW) or VEH on alcohol intake 
in the P rats depicted in (A) during the 5 days of drug treatment preceding BAC determination. 
Each point represents the mean  S.E. 
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